Product category:
Clinical chemistry analysis
News Release from: Perkin Elmer LAS (UK)
Edited by the Laboratorytalk Editorial
Team on 16 September 2004
Biomarker platform accelerates drug
development
PerkinElmer announces agreement with Predictive Diagnostics that allows for comprehensive biomarker platform development aimed at accelerating drug development and diagnostics
PerkinElmer and Predictive Diagnostics (PDI), a clinical proteomics company and wholly owned subsidiary of Large Scale Biology, have entered into a collaborative partnership for advanced biomarker discovery technology to accelerate drug development and diagnostic testing PerkinElmer will provide access to PDI's proprietary biomarker amplification filter (Bamf) technology customised for PerkinElmer's Protof 2000 Maldi O-Tof mass spectrometer to create the 'industry standard' platform for biomarker discovery and analysis
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
PerkinElmer's Life and Analytical Sciences sales and marketing team will exclusively offer PDI's Bamf technology services to leading pharmaceutical companies and major research institutions.
PDI's Bamf technology is a comprehensive suite of in silico machine learning technologies and advanced informatics tools that use a simple blood test for the discovery of biomarker fingerprints to diagnose diseases utilising high-resolution mass spectrometry data.
PDI has developed its Bamf technology for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases.
Further reading
Protein workstation details revealed
Claimed to be the first of its kind, this workstation fully automates the processing of microscope slide-based protein microarrays
More genes in human cDNA microarray
Human cDNA microarray system for researchers seeking access to premium gene content as well proprietary detection technology for ultra-sensitive gene expression results
"Predictive Diagnostics is a recognised leader in biomarker analysis software.
"Its proprietary set of algorithms and informatics capabilities will complement our mass spectrometry and proprietary consumables offerings and complete our total solution for biomarker discovery and screening" said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"We believe this solution will be enabling technology for our pharmaceutical, biotech, and academic customers in the proteomic biomarker field".
PerkinElmer's Protof 2000 is part of the company's high content proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer.
Using advanced, innovative technologies, like the Protof 2000 Maldi O-Tof, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility.
"PerkinElmer is the leader in state-of-the-art proteomic hardware and advanced purification solutions needed for advanced proteomic biomarker analysis," said Kevin Ryan, CEO of Predictive Diagnostics.
"We are confident that the combined strength of PerkinElmer's proteomic hardware and PDI's portfolio of discovery and diagnostic solutions will add significant value to our pharmaceutical and life sciences customers.".
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
